In July 2026, the FDA took two separate actions related to peptides, but they are often reported as one. This article explains what is actually happening, what it means for compounded peptides, and what regulatory steps remain before broader use becomes possible.
The core issue of the hearing
BPC-157 is currently under review by the FDA Pharmacy Compounding Advisory Committee. The core issue is whether BPC-157 and other Category 2 peptides can be legally produced by 503A compounding pharmacies, or whether they will remain strictly prohibited.
This review is not a final conclusion on BPC-157’s safety or efficacy. It is about whether it can be included in the legal production scope of compounding pharmacies. This is a regulatory pathway issue, not an efficacy determination.
What it means for compounded peptides
If the PCAC decides to allow 503A pharmacies to produce Category 2 peptides like BPC-157, it would mean these peptides can be compounded by licensed pharmacies with a prescription. This would provide a legal access pathway for patients and doctors, but it would not mean these peptides have received FDA new drug approval.
If the PCAC decides to maintain the prohibition, these peptides would remain accessible only through research-use channels or gray markets, and quality control and safety risks would persist.
What regulatory steps remain
Even if the PCAC makes a favorable decision, multiple steps remain: clarifying production standards for compounding pharmacies, quality control requirements, labeling standards, and guidelines for physician prescribing and patient monitoring. In addition, large-scale human clinical trials remain necessary for full new drug approval.
The difference between RUO labels and compounded prescriptions
Peptides labeled “for research use only” (RUO) bypass FDA regulation and lack guarantees of purity, sterility, or dose verification. Compounded prescription drugs, by contrast, are strictly tested and regulated by licensed pharmacies. This distinction is critical for users.
Conclusion
The July 2026 hearing is a regulatory turning point, but it is not the endpoint. Understanding the actual issues and subsequent steps helps form a rational view of the future of BPC-157 and other Category 2 peptides.